Current Baylor Vaccine Research Center activities include preclinical research, clinical trials, laboratory support and discovery, and training the next generation of vaccinologists. Below is a listing of the center's strengths, expertise and collaboration:

Center Strengths

  • One of nine NIH-sponsored Vaccine and Treatment Evaluation Units
  • One of five US Influenza Vaccine Effectiveness Units (laboratory component)
  • U01 for evaluation of predictors of recurrent wheezing/asthma in infants
  • Site for screening and evaluation of antivirals and vaccines for prevention and treatment of paramyxovirus infections (such as respiratory syncytial virus, or RSV) using in vitro and animal models


  • Vaccine evaluation among diverse populations
  • Antiviral screening and evaluation in animals and humans
  • Molecular epidemiology and surveillance
  • Development of laboratory assays for assessing immune responses to respiratory virus infections, including diagnostics, culture and molecular detection methods
  • Evaluating the pathogenesis of disease and determining correlates of immunity
  • Methodology for the development of aerosols for delivery of vaccines and antivirals to animal models of respiratory diseases and treat human respiratory infections


  • Strong collaborations with the Center for Metagenomics and Microbiome Research, and with faculty who have expertise in the areas of immunogenetics, transcriptome analyses and bioinformatics
  • International collaborations: Proposed projects with Brazil and Guatemala and one additional international site proposed as part of our recent VTEU contract; in Lima, Peru (Cayetano Heredia).
  • Ongoing collaboration in Santiago, Chile on the changing trends in the molecular epidemiology of RSV
  • Local and regional collaborations (UTMB, TCH, MEDVAMC, MD Anderson, UT-Houston, Kelsey Seybold, and private practitioners.)